Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Cistus: A Natural Antibiotic, Antiviral, and Biofilm Buster

ACTION ALERT: Improve US Chronic Pain Care

Big step towards cure for HIV and other lifelong viral infections

How Omega-3 Fights Depression

SURVEY RESULTS: Attitudes About Fatigue

Rejuvenate Your Skin Naturally With Sea Buckthorn Oil

A Smile

Can Drinking More Water Help You Lose Weight?

Superfood Trio: Ginger, Turmeric, and Carrots?

Tropical Turmeric Carrot Juice & Smoothie

 
Print Page
Email Article

9.5-Year Follow-Up on Effects of Rituximab in RA Patients

  [ 6 votes ]   [ Discuss This Article ]
www.ProHealth.com • November 9, 2012


Article:
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
– Source: Annals of Rheumatic Diseases, Nov 7, 2012

By Ronald F van Vollenhoven, et al.

[Note: The full text of this article is available free here. Rheumatoid arthritis is associated with elevated risks of serious infections, lymphomas and fatal cardiovascular events. The drug rituximab is used in combination with methotrexate to control autoimmune damage to RA patients' joints by reducing levels of a specific immune B-cell that attacks them. The therapy initially elevates risk of infection and malignancy somewhat. This long-term tracking study reflected a concern about the possibility that repeated courses of rituximab might further increase these risks. The findings will be of interest to researchers conducting experimental trials of rituximab as a potential treatment for ME/CFS as well.]

Abstract:
Objectives: Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA).

Methods:

Pooled observed case analysis of data from patients with moderate-to-severe, active RA treated with rituximab in a global clinical trial program.

Results:
As of September 2010, 3,194 patients had received up to 17 rituximab courses over 9.5 years (11,962 patient-years). Of these, 627 had more than 5 years' follow-up (4,418 patient-years).

A pooled placebo population (n=818) (placebo + methotrexate (MTX)) was also analyzed.

Serious adverse event and infection rates generally remained stable over time and multiple courses.

• The overall serious infection event (SIE) rate was 3.94 per 100 patient-years (3.26 per 100 patient-years in patients observed for more than 5 years) and was comparable with placebo+MTX (3.79 per 100 patient-years).

• Serious opportunistic infections were rare.

• Overall, 22.4% (n=717) of rituximab-treated patients developed low immunoglobulin (Ig)M and 3.5% (n=112) low IgG levels for 4 months or more after 1 or more courses.

• Serious infection event rates were similar before and during/after development of low Ig levels; however, in patients with low IgG, rates were higher than in patients who never developed low IgG.

• Rates of myocardial infarction and stroke were consistent with rates in the general RA population.

• No increased risk of malignancy over time was observed.

Conclusion:

This analysis demonstrates that rituximab remains generally well tolerated over time and multiple courses, with a safety profile consistent with published data and clinical trial experience.

Overall, the findings indicate that there was no evidence of an increased safety risk or increased reporting rates of any types of adverse events with prolonged exposure to rituximab during the 9.5 years of observation.

Source: Annals of the Rheumatic Diseases, Nov 7, 2012. PMID:23136242, by van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB. Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden. [Email: ronald.van.vollenhoven@ki.se]





Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Energy NADH™ 12.5mg Optimized Curcumin Longvida®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Enhance Eyelashes Naturally Enhance Eyelashes Naturally
Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World
Natural Support for Mood, Sleep and Mental Focus? L-theanine Natural Support for Mood, Sleep and Mental Focus? L-theanine
D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map